In an early study, a new experimental drug for Alzheimer's disease has already exceeded high expectations.
The results of the trial of an antibody known as aducanumab, have shown some benefit in people who were given it in the very earliest stage of the disease, the Guardian reported. In the trial, conducted primarily to ensure the drug was safe and had no serious side-effects, brain scans showed a reduction of amyloid plaque, whose accumulation is thought to be one of the major causes of Alzheimer's.
Risk Factors for Alzheimers Disease
Cognitively normal adults exhibiting atrophy of their temporal lobe or damage to blood vessels in the brain are more likely to develop Alzheimer's disease.
Advertisement
The higher the dose of drug the patient was given, the greater the reduction and tests also showed that those people who took the drug had a slower rate of mental decline than those who did not.
Eric Karran, director of research at Alzheimer's Research UK, said that these are very promising early results, which not only demonstrate the safety of this treatment, but also suggest it may hold benefits in the early stages of Alzheimer's disease.
![Inability to Recognize Familiar Smells Could Signal Alzheimers]( "Inability to Recognize Familiar Smells Could Signal Alzheimers")
People who have difficulty recognizing familiar smells could be experiencing an early sign of Alzheimer's disease, according to a study published Monday.
Karran added that while many previous anti-amyloid therapies have failed to meet their goals, these preliminary findings back up research suggesting that treatments targeting amyloid will need to be given early in the disease.
Karran noted that further data from this trial is yet to be reported, and it will be important to see this data as well as results from much larger trials before we can understand how effective this treatment may be.
Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, the company that made the drug, announced it would be moving quickly into large-scale trials which will involve hundreds, if not thousands, of people.
The trial results were presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.
Source: ANI
Inability to Recognize Familiar Smells Could Signal Alzheimers
People who have difficulty recognizing familiar smells could be experiencing an early sign of Alzheimer's disease, according to a study published Monday.
Advertisement
Karran added that while many previous anti-amyloid therapies have failed to meet their goals, these preliminary findings back up research suggesting that treatments targeting amyloid will need to be given early in the disease.
Karran noted that further data from this trial is yet to be reported, and it will be important to see this data as well as results from much larger trials before we can understand how effective this treatment may be.
Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, the company that made the drug, announced it would be moving quickly into large-scale trials which will involve hundreds, if not thousands, of people.
The trial results were presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.
Source: ANI
Lack of Vitamin D Linked to Higher Risk of Dementia
Older people who do not get enough vitamin D face a much higher risk of Alzheimer's disease or dementia, the largest study of its kind on the topic said.
Advertisement
 Young Blood to Cure Decline of Aging BrainA research showed that injections of juvenile mouse blood boosts learning and memory in older rodents, findings that hold the long-sought cure for the decline of ageing brain. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
